Načítá se...

Effects of the NK(1) Antagonist, Aprepitant, on Response to Oral and Intranasal Oxycodone in Prescription Opioid Abusers

Preclinical studies suggest that the NK(1) receptor may modulate the response to opioids, with NK(1) inactivation leading to decreased opioid reinforcement, tolerance and withdrawal. Aprepitant is a selective NK(1) antagonist currently marketed for clinical use as an anti-emetic. This 6-week inpatie...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Addict Biol
Hlavní autoři: Walsh, Sharon L., Heilig, Markus, Nuzzo, Paul A., Henderson, Pam, Lofwall, Michelle R.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4354863/
https://ncbi.nlm.nih.gov/pubmed/22260216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1369-1600.2011.00419.x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!